Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib 400 mg versus 600 mg in newly diagnosed chronic-phase chronic myeloid leukemia
CTR20212881Phase 4Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Flumatinib in chronic myelogenous leukemia (CML), sponsored by Hengrui Therapeutics. Started Nov 2021; status: completed.
02
Drugs
Flumatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20212881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212881.